Barclays restated their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK – Get Rating) in a research note issued to investors on Tuesday morning, Marketbeat reports. Barclays currently has a GBX 2,500 ($31.46) target price on the stock.
Separately, Morgan Stanley reiterated an equal weight rating on shares of Hikma Pharmaceuticals in a report on Wednesday, May 11th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of Hold and an average price target of GBX 2,444.29 ($30.76).
Shares of HIK opened at GBX 1,688.50 ($21.25) on Tuesday. Hikma Pharmaceuticals has a 1-year low of GBX 1,631.50 ($20.53) and a 1-year high of GBX 2,703 ($34.01). The company has a 50-day moving average of GBX 1,924.78 and a 200 day moving average of GBX 2,049.24. The firm has a market capitalization of £3.82 billion and a price-to-earnings ratio of 11.46. The company has a debt-to-equity ratio of 34.29, a current ratio of 2.06 and a quick ratio of 1.31.
About Hikma Pharmaceuticals (Get Rating)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.